Digestive AdvantageTM Gas Defense Formula (GD) group	Placebo group	Improvement in GSRS (Gastrointestinal Symptom Rating Scale) SF-36v2 MCS score - in adults with post prandial intestinal gas-related symptoms and no GI diagnoses	19042	19290	While other efficacy endpoints do not indicate statistical significance for GD relative to placebo, all but the SF-36v2 MCS and the VAS-Gas score showed differences in the direction that indicates a larger beneficial effect for GD than for placebo.
Digestive AdvantageTM Gas Defense Formula (GD) group	Placebo group	Improvement in GSRS (Gastrointestinal Symptom Rating Scale) abdominal distension subscore - in adults with post prandial intestinal gas-related symptoms and no GI diagnoses	1367	1449	strong trend for improvement on the GSRS abdominal distension subscore (p = 0.061)
Digestive AdvantageTM Gas Defense Formula (GD) group	Placebo group	Improvement in GSRS (Gastrointestinal Symptom Rating Scale) VAS-Gas score - in adults with post prandial intestinal gas-related symptoms and no GI diagnoses	19042	19290	While other efficacy endpoints do not indicate statistical significance for GD relative to placebo, all but the SF-36v2 MCS and the VAS-Gas score showed differences in the direction that indicates a larger beneficial effect for GD than for placebo.
Digestive AdvantageTM Gas Defense Formula (GD) group	Placebo group	Improvement in GSRS (Gastrointestinal Symptom Rating Scale) total score - in adults with post prandial intestinal gas-related symptoms and no GI diagnoses	16685	16930	GD performed significantly or nearly significantly better than placebo for the following endpoints (Tables 3, 4 and 5): GSRS: abdominal pain subscore (p = 0.046), GSRS: abdominal distension subscore (p = 0.061), and GSRS total score (p = 0.048).
Digestive AdvantageTM Gas Defense Formula (GD) group	Placebo group	Improvement in GSRS (Gastrointestinal Symptom Rating Scale) abdominal pain subscore - in adults with post prandial intestinal gas-related symptoms and no GI diagnoses	1182	1358	Measured against the placebo, subjects in the probiotic group achieved significant improvements in GSRS abdominal pain subscore (p = 0.046) and the GSRS total score (p = 0.048)
Digestive AdvantageTM Gas Defense Formula (GD) group	Placebo group	Improvement in GSRS (Gastrointestinal Symptom Rating Scale) total score - in adults with post prandial intestinal gas-related symptoms and no GI diagnoses	1182	1450	Measured against the placebo, subjects in the probiotic group achieved significant improvements in GSRS abdominal pain subscore (p = 0.046) and the GSRS total score (p = 0.048), with a strong trend for improvement on the GSRS abdominal distension subscore (p = 0.061).
Digestive AdvantageTM Gas Defense Formula (GD) group	Placebo group	Improvement in GSRS (Gastrointestinal Symptom Rating Scale) abdominal distension subscore - in adults with post prandial intestinal gas-related symptoms and no GI diagnoses	1182	1450	Measured against the placebo, subjects in the probiotic group achieved significant improvements in GSRS abdominal pain subscore (p = 0.046) and the GSRS total score (p = 0.048), with a strong trend for improvement on the GSRS abdominal distension subscore (p = 0.061).
Digestive AdvantageTM Gas Defense Formula (GD) group	Placebo group	Improvement in GSRS (Gastrointestinal Symptom Rating Scale) abdominal pain subscore - in adults with post prandial intestinal gas-related symptoms and no GI diagnoses	1182	1450	Measured against the placebo, subjects in the probiotic group achieved significant improvements in GSRS abdominal pain subscore (p = 0.046) and the GSRS total score (p = 0.048), with a strong trend for improvement on the GSRS abdominal distension subscore (p = 0.061).
